All articles from EyeWorld.org on the topic of blepharitis. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
Blepharitis diagnosis and treatment have shifted in recent years, from the ability to diagnose blepharitis subtypes to the ability to treat those subtypes specifically. Overall, it’s becoming a more treatable ocular surface disease, and three experts had something to say about it.
Several years ago, the ASCRS Cornea Clinical Committee created the ASCRS Preoperative OSD Algorithm because of the lack of awareness and consensus regarding recommendations on ocular surface disease. The Committee is currently working on updates to the algorithm as new therapies have been introduced.
When treating dry eye patients, it’s possible to encounter patients who do not respond to treatment. Two experts discussed how to proceed in approaching these patients and getting them the care they need.
“Best practices are the summation of the technical aspects of medicine. They are, in effect, the perfection of the form of medicine,” said Julie Schallhorn, MD. She shared this and other thoughts on best practices and gave a preview of the articles in the Cornea section of the issue.
Blepharitis is commonly seen by ophthalmologists. This inflammation of the eyelid margins can be acute or chronic and has a multitude of etiologies. This article gives an in-depth look at the condition, with helpful insights from two experts.
➤ FDA approves AI-based diabetic retinopathy screener ➤ FDA accepts NDA for Demodex treatment ➤ Phase 2b results for MGD therapy ➤ Phase 1/2 trial evaluates investigational TED treatment ➤ Phase 1 clinical trial to study synthetic cannabinoid derivative for glaucoma ➤ OCT company rebrands ➤ ASCRS news and events
➤ Launch of IOL made with new ‘glistening-free’ material ➤ Enrollment complete in study of mydriasis-reversing drop in a pediatric group ➤ Acquisition of electrophysiology medical device company ➤ Licensing of investigational neuroprotective drug ➤ ASCRS news and events
Rosacea can be a significant problem for many patients and may be more prevalent than physicians think. Depending on the subtype, there may be ocular involvement. Three physicians discussed treatment strategies, in addition to sharing what to look for and how to diagnose.
➤ FDA approves generic Restasis ➤ Phase 3 trial for novel, preservative-free drug delivery platform ➤ Enrollment complete for Phase 3 blepharitis trial ➤ Enrollment complete for Phase 3 mydriasis reversal study ➤ Path forward for resubmission of drug-device combination product ➤ ‘Immunity and Inflammation in the Anterior Segment of the Eye’ report ➤ ASCRS news and events
➤ Positive topline results from Phase 3 trial for first-in-class dry eye drop ➤ Study: Long-term efficacy of neuromyelitis optica spectrum disorder treatment ➤ Long-term data from gene therapy injection for wet AMD ➤ Positive data from Phase 1/2 trial of gene therapy for geographic atrophy ➤ Ophthalmic device company partners with augmented reality tech company
Get the latest ophthalmology news delivered to your inbox every Friday.